|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Potential utility of anti-TNF drugs in synovial chondromatosis associated with ankylosing spondylitis.
|
31647182 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Meanwhile, TNF inhibitors appear to have different safety profiles in ankylosing spondylitis and rheumatoid arthritis.
|
30476367 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To describe the use of tumor necrosis factor-alpha inhibitors (TNFis) among pregnancies ending in a live birth and with a diagnosis of ankylosing spondylitis (AS), Crohn's disease (CD), juvenile idiopathic arthritis (JIA), psoriasis (PsO), psoriatic arthritis (PsA), rheumatoid arthritis (RA), or ulcerative colitis (UC).
|
30430682 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
From PSARA, a prospective observational study, we examined 51 SpA patients (31 psoriatic arthritis (PsA), and 20 ankylosing spondylitis (AS)), starting tumor necrosis factor (TNF) inhibitor alone (n = 25), combined with methotrexate (MTX) (n = 10), or MTX monotherapy (n = 16).
|
31335881 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, little is known about the effect of TNF-α blocker treatment on the gut microbiota in ankylosing spondylitis.
|
31556231 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that rifaximin significantly reduced the severity of AS and resulted in down-regulation of inflammatory factors, such as TNF-α, IL-6, IL-17A, and IL-23.
|
30886835 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum TRAIL-R1 and TNF-α levels were increased in patients with AS compared with healthy controls (4.5 ± 2.3 vs 3.5 ± 2.3 pg/mL, p = 0.036; 3.8 [1.6-7.7] vs 2.0 [0.21-5.7] pg/mL, p = 0.048, respectively).
|
31094932 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
For example, tumor necrosis factor inhibitors are quite successful in the treatment of rheumatoid arthritis (RA), Behçet's disease (BD), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) but not in that of systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's syndrome (SS) and antineutrophil cytoplasmic antibody-associated vasculitis (AAV), conversely, RA shares genetic backgrounds more with SLE, SSc, SS and AAV than BD, AS and PsA.
|
29623390 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiRNA-5196 expression was significantly higher in patients with RA and AS before TNF-α therapy than in those following anti-TNF-α therapy and healthy controls.
|
29744553 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High disease activity AS patients were treated with TNFα inhibitors for 12 weeks.
|
29546695 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis.
|
29335342 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using the Ankylosing Spondylitis Disease Activity Score (ASDAS), we assessed the prevalence of ID in ax-SpA patients treated with TNFα inhibitors (TNFi).
|
28880727 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, the IL-10-819 C/T and TNF-α-857 C/T polymorphisms also confer susceptibility to AS, especially in Asian population.
|
30322951 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
No differences were found in IMT values at the level of internal carotid between the 2 populations.The significantly lower carotid atherosclerosis found in patients with AS treated with TNF antagonists than in healthy controls shows the important complementary role of this treatment in reducing vascular disease progression probably by decreasing inflammation.
|
29979389 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
TNF-α antagonist indications were ankylosing spondylitis (n = 8), inflammatory bovel diseases (n = 7) and rheumatoid arthritis (n = 4).
|
29028148 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Certolizumab-pegol is the first and only pegylated TNF-α antagonist approved in the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
|
30225952 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumour necrosis factor (TNF)-α inhibitors are highly used in Romania for the treatment of autoimmune disorders, such as rheumatoid arthritis (RA), psoriasis, inflammatory bowel diseases, and ankylosing spondylitis.
|
29792084 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
RESULTS The results suggest that AS mice has higher levels of TNF-α, IL-1β, and IL-6 (p<0.01 for all), and lower levels of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-PX) (p<0.01 for all).
|
29849019 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-tumor necrosis factor-alpha (TNFα) was not associated with MS risk in persons with inflammatory bowel disease (standard morbidity ratio = 4.2;95%CI:0.1-23.0) and arthritis (standardized incidence ratio = 1.38;95%CI:0.69-2.77); however, men exposed to anti-TNFα who also had arthritis and individuals with ankylosing spondylitis were at an increased risk (standardized incidence ratios = 3.91;95%CI:1.47-10.42 and 3.48;95%CI:1.45-8.37, respectively).
|
29210147 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We tested the discriminatory capacity of diffusion-weighted magnetic resonance imaging (DWI) and its potential as an objective measure of treatment response to tumor necrosis factor inhibition in ankylosing spondylitis (AS).
|
29449501 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice.
|
29611349 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort.
|
29449504 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The successful therapeutic use of anti-TNF biological agents in patients with ankylosing spondylitis (AS) indicates that tumor necrosis factor-α (TNF-α) and tumor necrosis factor receptor (TNFR) genes are involved in the pathogenesis of AS.
|
30075559 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effect of tumor necrosis factor α inhibitors on spinal radiographic progression in patients with ankylosing spondylitis.
|
29611287 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This retrospective cohort study included all AS patients (n = 1055) who have been treated with either TNF inhibitor or NSAIDs at the Seoul National University Hospital from 2004 to 2016.
|
30076542 |
2018 |